| Source: HalifaxProj(activate) |
| Type: |
| Autophagy genes, including Atg3, Atg5, Atg6, Atg7, Atg10, Atg12, and Atg17. Tumor autophagy refers to the process by which cancer cells degrade and recycle cellular components through autophagy, a cellular mechanism that helps maintain homeostasis and respond to stress. Autophagy can have dual roles in cancer, acting as both a tumor suppressor and a promoter, depending on the context. Authophagy is the process used by cancer cells to “self-eat” to survive. Authophagy can be both good and bad. If authophagy is prolonged this will become a lethal process to cancer. On the other hand, for a short while (e.g. during chemotheraphy, radiotheraphy, etc.) authophagy is used by cancer cells to survive. For example, Chloroquine is a blocker of autophagy and has been used in a lab setting to dramatically enhance tumor response to radiotherapy, chemotherapy. |
| 2432- | 2DG, | Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth |
| - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | KP2 | - | in-vivo, | NA, | NA |
| 5271- | 3BP, | The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside |
| - | Review, | Var, | NA |
| 5263- | 3BP, | CET, | 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | HCT116 |
| 5270- | 5-ALA, | PDT, | 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy |
| - | Review, | Var, | NA |
| 5430- | AG, | Review of the pharmacological effects of astragaloside IV and its autophagic mechanism in association with inflammation |
| - | Review, | Stroke, | NA |
| 5431- | AG, | Advances in research on the anti-tumor mechanism of Astragalus polysaccharides |
| - | Review, | Var, | NA |
| 5432- | AG, | Astragalus polysaccharides combined with radiochemotherapy for cervical cancer: a systematic review and meta-analysis of randomized controlled studies |
| - | Review, | Cerv, | NA |
| 4559- | AgNPs, | Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | Caco-2 |
| 5146- | AgNPs, | Silver Nanoparticle-Induced Autophagic-Lysosomal Disruption and NLRP3-Inflammasome Activation in HepG2 Cells Is Size-Dependent |
| - | in-vitro, | Liver, | HepG2 |
| 328- | AgNPs, | Rad, | Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma |
| - | vitro+vivo, | GBM, | U251 |
| 343- | AgNPs, | Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma |
| - | in-vitro, | PC, | PANC1 |
| 330- | AgNPs, | Rad, | Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs |
| - | in-vitro, | GBM, | U251 |
| 329- | AgNPs, | Rad, | Enhancement of radiotherapy efficacy by silver nanoparticles in hypoxic glioma cells |
| - | in-vitro, | GBM, | U251 |
| 327- | AgNPs, | MS-275, | Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells |
| - | in-vitro, | Lung, | A549 |
| 318- | AgNPs, | Silver nanoparticles regulate autophagy through lysosome injury and cell hypoxia in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 317- | AgNPs, | Autophagic effects and mechanisms of silver nanoparticles in renal cells under low dose exposure |
| - | in-vitro, | Kidney, | HEK293 |
| 312- | AgNPs, | wortm, | Inhibition of autophagy enhances the anticancer activity of silver nanoparticles |
| - | vitro+vivo, | Cerv, | HeLa |
| 400- | AgNPs, | MF, | Polyvinyl Alcohol Capped Silver Nanostructures for Fortified Apoptotic Potential Against Human Laryngeal Carcinoma Cells Hep-2 Using Extremely-Low Frequency Electromagnetic Field |
| - | in-vitro, | Laryn, | HEp2 |
| 2648- | AL, | Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway |
| - | in-vitro, | OS, | SaOS2 | - | in-vivo, | OS, | NA |
| 2666- | AL, | Targeting the Interplay of Autophagy and ROS for Cancer Therapy: An Updated Overview on Phytochemicals |
| - | Review, | Var, | NA |
| 1069- | AL, | Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | Nor, | Het-1A |
| 250- | AL, | Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells |
| - | in-vitro, | Liver, | HepG2 |
| 280- | ALA, | Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition |
| - | in-vivo, | Lung, | A549 |
| 1354- | And, | Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer |
| - | in-vitro, | PC, | NA | - | in-vivo, | PC, | NA |
| 1553- | Api, | Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy |
| - | Review, | NA, | NA |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 2631- | Api, | Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells |
| - | in-vivo, | GC, | NA | - | in-vitro, | GC, | AGS |
| 2635- | Api, | CUR, | Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2638- | Api, | Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death |
| - | in-vitro, | lymphoma, | PEL |
| 1008- | Api, | Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 313- | Api, | Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells |
| - | in-vitro, | Thyroid, | BCPAP |
| 3382- | ART/DHA, | Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge? |
| - | Review, | Var, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 3396- | ART/DHA, | Progress on the study of the anticancer effects of artesunate |
| - | Review, | Var, | NA |
| 5380- | ART/DHA, | Artemisinin and Its Derivatives as Potential Anticancer Agents |
| - | Review, | Var, | NA |
| 5376- | ART/DHA, | Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | SW48 | - | in-vitro, | BC, | MDA-MB-453 |
| 5137- | ART/DHA, | Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin |
| - | vitro+vivo, | ESCC, | Eca109 |
| 5134- | ART/DHA, | Dihydroartemisinin induces autophagy by suppressing NF-κB activation |
| - | in-vitro, | Var, | NA |
| 5133- | ART/DHA, | Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 556- | ART/DHA, | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
| - | Review, | NA, | NA |
| 558- | ART/DHA, | Artemisinin and Its Synthetic Derivatives as a Possible Therapy for Cancer |
| - | Review, | NA, | NA |
| 1076- | ART/DHA, | The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer |
| - | Review, | NA, | NA |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 5173- | Ash, | 2DG, | Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | T47D |
| 5451- | ATV, | In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | A172 |
| 5448- | ATV, | Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology |
| - | Review, | Var, | NA |
| 4981- | ATV, | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
| 5505- | Ba, | Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway |
| - | in-vitro, | Thyroid, | NA |
| 5501- | Ba, | Therapeutic effects and mechanisms of action of Baicalein on stomach cancer: a comprehensive systematic literature review |
| - | Review, | GC, | NA |
| 5250- | Ba, | Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:321 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid